Pharmacokinetics of oral moclobemide in healthy human subjects and effects on MAO-activity in platelets and excretion of urine monoamine metabolites.
The plasma concentrations of the MAO-inhibitor moclobemide (Ro 11-1163) were determined in six healthy male subjects after oral (tablets) administration. Effects on MAO activity in platelets and excretion of monoamine metabolites in urine were investigated. The design of the study was a double-blind cross-over study with single oral doses of placebo, 50, 100 and 200 mg of moclobemide. The elimination profile of the drug showed that the half life of the unchanged drug ranged between 1 and 2 h except in one subject with a half-life of about 4 h. The mean bioavailability calculated using flow model concepts was F = 0.43 after 50 mg, F = 0.47 after 100 mg and F = 0.59 after 200 mg. The outlier with a t 1/2 of 4 h was found to have a bioavailability of more than 0.80 after all 3 doses. The slightly increasing bioavailability with higher doses was interpreted as evidence of saturable hepatic first-pass elimination of the drug. MAO activity in platelets was measured before and 2, 6 and 24 h after drug administration. No inhibition of platelet MAO was obtained at any point in time or dose level, as to be expected since moclobemide preferentially inhibits MAO A. Urine excretion of the monoamine metabolites homovanillic acid (HVA), dihydroxyphenylacetic acid (DOP-AC), 3-methoxy-4-hydroxy-phenylglycol (MOPEG) and 5-hydroxyindoleacetic acid (5-HIAA) was followed during 48 h after placebo, 50 and 200 mg of moclobemide. Time but not dose contributed significantly to the variability in excretion of the monoamine metabolites.(ABSTRACT TRUNCATED AT 250 WORDS)
D000284:Administration, Oral; D000328:Adult; D001549:Benzamides / Q000009:adverse effects / Q000378:metabolism* / Q000494:pharmacology; D001679:Biogenic Amines / Q000652:urine*; D001682:Biological Availability; D001792:Blood Platelets / Q000201:enzymology*; D001794:Blood Pressure / Q000187:drug effects; D006207:Half-Life; D006801:Humans; D007700:Kinetics; D008297:Male; D020912:Moclobemide; D008995:Monoamine Oxidase / Q000097:blood*; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects / Q000378:metabolism* / Q000494:pharmacology
D001549:Benzamides; D001679:Biogenic Amines; D008996:Monoamine Oxidase Inhibitors; D008995:Monoamine Oxidase; D020912:Moclobemide